Month: August 2020

CHRISTIANSTED, U.S. Virgin Islands, Aug. 10, 2020 (GLOBE NEWSWIRE) — Front Yard Residential Corporation (“Front Yard” or the “Company”) (NYSE: RESI) today announced its financial and operating results for the second quarter of 2020.Second Quarter 2020 Highlights and Recent DevelopmentsRental revenues increased to $55.1 million for the second quarter of 2020, up 1.5% over the first quarter of 2020 and up 6.9% year on year.Core Funds from Operations (“FFO”) were $0.18 per diluted share, an improvement of $0.06 per diluted share over the first quarter of 2020 and up $0.13 year on year.1Adjusted FFO was $0.09 per diluted share for the second quarter of 2020.1Stabilized Rental leased percentage was 98.3%, up from 97.0% as of March 31, 2020 and 94.1% as of June 30, 2019.Blended rent growth of 4.1%, with renewal rent growth of 4.1% and...

Finalizing preparations for pharmacokinetic (PK) clinical trials of AQST-108First planned PK clinical trial expected to begin during the third quarter of 2020WARREN, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of allergic reactions (Type 1), including anaphylaxis, using Aquestive’s proprietary PharmFilm® technologies. Fast Track is an FDA process designed to facilitate...

MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced the U.S. Food and Drug Administration (FDA) granted the fourth Orphan Drug Designation (ODD) for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases. Retinitis Pigmentosa (RP) caused by PDE6B mutation is an inherited retinal dystrophy that leads to blindness by midlife and is characterized by the progressive loss of photoreceptors, with or without the loss of retinal pigment epithelium cells. At least one mutation in the PDE6B gene has been found to cause autosomal dominant congenital stationary night blindness, which is characterized by the inability to see in low light.Ocugen’s Modifier...

CUPERTINO, CA, Aug. 10, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Aemetis, Inc. (NASDAQ: AMTX) announced that the company will host a conference call to review the release of its second quarter 2020 earnings report:Date: Thursday, August 13, 2020Time: 11 am Pacific Standard Time (PST)Live Participant Dial In (Toll Free): +1-844-602-0380Live Participant Dial In (International): +1-862-298-0970Webcast URL: https://www.webcaster4.com/Webcast/Page/2211/36421Attendees may submit questions during the Q&A portion of the conference call. After August 13th, the webcast will be available on the Company’s website (www.aemetis.com) under Investors/Conference Calls. The voice recording will also be available through August 20, 2020 by dialing (Toll Free) 877-481-4010 or (International) 919-882-2331 and entering conference ID number 36421. About...

Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021C9orf72 and SNP3 clinical trial applications on track to be submitted in 4Q 2020ADAR editing advancing with additional in vivo data expected at upcoming Analyst & Investor Research WebcastWave to host investor conference call and webcast at 8:30 a.m. ET todayCAMBRIDGE, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.Recent business highlightsPRECISION-HD programs for Huntington’s disease (HD): Wave is developing a unique portfolio of investigational stereopure...

VANCOUVER, British Columbia, Aug. 10, 2020 (GLOBE NEWSWIRE) — Serengeti Resources Inc. (SIR: TSX-V) (“Serengeti” or “the Company”) is pleased to report that Phase 1 exploration on its Kwanika Copper Gold project is completed and Phase 2 which includes drilling is to begin shortly. The Kwanika project is ~26,000 hectares, held by Kwanika Copper Corporation (KCC)* and located in the northern Quesnel Trough of British Columbia which hosts numerous porphyry copper-gold deposits.The 2020 drill program is fully funded and designed to expand the known resource which is open in several directions and provide a deep test for the potential of a gold enriched target first identified from drilling in 2016 as well as testing several other ideas.David Moore, President and CEO of Serengeti commented, “We are pleased to...

FREDERICK, MD, Aug. 10, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – BioElectronics Corporation (OTC: BIEL), (www.bielcorp.com) today released a Chairman’s Letter to Shareholders written by Dr. Richard Staelin, the Company’s Chairman of the Board.Dear BioElectronics Shareholders :The purpose of this letter is to update you on the activities of BioElectronics Corporation over the last 10 months, their results, and the impact of these activities on the future of the Company. Although many are probably most eager to learn about these results (which are detailed first), I encourage you to also read my discussion on the underlying logic which led us to where we are today, since it is this logic that forms the foundation that will drive your Company forward over the foreseeable future.Results to Date1. We now have signed long term contracts...

Interim RMC-4630 Data Support Benefit of Intermittent Dosing and Corroborate Clinical Activity Against Genetically-Defined TumorsTargeted Combination Strategy Underpins Initiation of New Clinical Trials Evaluating RMC-4630 with KRASG12C Inhibitor or Anti-PD-1 Antibody$179.4 Million Follow-On Offering Strengthens Balance SheetREDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced its financial results for the second quarter and six months ended June 30, 2020, and provided an update on its R&D pipeline and other corporate developments.“Revolution Medicines continues pursuit of its ambitious R&D strategy on behalf of cancer patients...

TORONTO, Aug. 10, 2020 (GLOBE NEWSWIRE) — Platinex Inc. (CSE: PTX) (the “Company” or “Platinex“) wishes to announce a non-brokered private placement up to $1,000,000 with a lead order from Palisades Goldcorp of $700,000.The non-brokered private placement (the “Private Placement“) shall consist of up to 14,285,715 units (“Units“) at $0.07/Unit to raise $1,000,000. Each Unit will consist of one common share (“Common Share“) of the Company and one Common Share purchase warrant (each a “Warrant“).  Each Warrant is exercisable into a Common Share at an exercise price of $0.10 for a period of 36 months following the closing of the Private Placement. The closing date of the Private Placement is anticipated to occur on or about August 24, 2020 or such other date determined...

WASHINGTON, Aug. 10, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that 26 professionals from the firm’s Corporate Finance & Restructuring segment have been named to the Who’s Who Legal: Restructuring & Insolvency Advisers 2020 list, up from 23 professionals in 2019.FTI Consulting had the most professionals of any firm named to the list, which recognizes the world’s leading restructuring and insolvency advisers based on nominations from peers outside of the legal sphere. In addition, FTI Consulting had two professionals recognized as Global Elite Thought Leaders for Restructuring & Insolvency, including David Griffin and Andrew Morrison. These experts received the highest number of nominations from peers.“In 2019, FTI Consulting was recognized by Who’s Who Legal as Restructuring & Insolvency...